Co-existence of chronic non-communicable diseases and common neoplasms among 2,462 endocrine adult inpatients – a retrospective analysis
More details
Hide details
Department of Oncological Endocrinology, Medical University of Lodz, Poland
Polish Mother’s Memorial Hospital & Research Institute, Lodz, Poland
1st Chair and Department of Cardiology, Medical University of Warsaw, Poland
Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Poland
Ann Agric Environ Med 2015;22(4):747–754
To analyze the coexistence of chronic non-communicable diseases (NCDs) and common neoplasms among endocrine adult inpatients.

Material and Methods:
The retrospective analysis was performed using clinical data of 2,462 adult patients (2,003 women and 459 men), hospitalized in the reference endocrine department. Diagnoses of 18 types of benign tumours and 16 types of malignant tumours, together with the most common 25 NCDs and demographic parameters, were all collected from the medical records. The most frequently found 6 types of benign tumours (of thyroid, pituitary, uterus, breast, adrenal and prostate) and 4 types of malignant tumours (of thyroid, breast, prostate and uterus) were taken for further statistical analyses.

Age predicted the existence of accumulated as well as individual types of benign and malignant tumours, whereas BMI predicted the occurrence of accumulated and some individual types of benign tumours. Accumulated as well as individual types of benign and malignant tumours coexisted more frequently with several NCDs, such as diabetes, hypertension, metabolic syndrome, osteoporosis, Graves’ disease, coronary artery disease, state after cholecystectomy, thus being disorders usually resulting from excessive exposure to harmful environmental factors. The most distinct coexistence was found between breast cancer and metabolic syndrome, between breast cancer and Graves’ disease, between cancer of the uterus and type 2 diabetes, between cancer of the uterus and metabolic syndrome, and between cancer of the uterus and dyslipidemia.

The results obtained indicate a significant relationship between the most common NCDs and several cancers in endocrine adult patients, which suggests that the prevention of the former may reduce the frequency of the latter.

Małgorzata Karbownik-Lewińska   
Department of Oncological Endocrinology, Medical University of Lodz, Poland
1. Stare SM, Jozefowicz JJ. The Effects of Environmental Factors on Cancer Prevalence Rates and Specific Cancer Mortality Rates in a Sample of OECD Developed Countries. Int J Appl Eco. 2008; 5(2): 92–115.
2. Thompson PA. Counterpoint: genetic risk feedback for common disease time to test the waters. Cancer Epidemiol Biomarkers Prev. 2007; 16(9): 1727–1729.
3. Dauvergne, P. Cancer and Global Environmental Politics: Proposing A New Research Agenda. Global Environ Polit. 2005; 5(3): 6–13.
4. Doll R. Epidemiological evidence of the effects of behaviour and the environment on the risk of human cancer. Recent Results Cancer Res. 1998; 154: 3–21.
5. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 13;343(2): 78–85.
6. Holly JM, Perks CM. Cancer as an endocrine problem. Best Pract Res Clin Endocrinol Metab. 2008; 22(4): 539–550.
7. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000; 21(3): 427–433.
8. Extermann M. Interaction between comorbidity and cancer. Cancer Control. 2007; 14(1): 13–22.
9. Karbownik-Lewinska M, Gesing A, Zasada K, Jedrzejczyk M, Sobieszczanska-Jablonska A, Krawczyk J, et al. Relationship between lipid peroxidation or carcinoembryonic antigen and risk factors for non-communicable diseases in women at midlife and beyond. Neuro Endocrinol Lett. 2012; 33(5): 536–545.
10. Karbownik-Lewinska M, Szosland J, Kokoszko-Bilska A, Stępniak J, Zasada K, Gesing A, et al. Direct contribution of obesity to oxidative damage to macromolecules. Neuro Endocrinol Lett. 2012; 33(4): 453–461.
11. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17): 1625–1638.
12. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302(5645): 643–646.
13. Carmichael AR, Bates T. Obesity and breast cancer: a review of the literature. Breast. 2004; 13(2): 85–92.
14. Weiss HA, Brinton LA, Potischman NA, Brogan D, Coates RJ, Gammon MD, et al. Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol. 1999; 28(5): 816–823.
15. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004; 159(12): 1160–1167.
16. Szychta P, Szychta W, Gesing A, Lewiński A, Karbownik-Lewińska M. TSH receptor antibodies have predictive value for breast cancer – retrospective analysis. Thyroid Res. 2013; 6(1): 1–8.
17. Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer. 2005;103(6): 1122–1128.
18. Kuijpens JL, Janssen-Heijnen ML, Lemmens VE, Haak HR, Heijckmann AC, Coebergh JW. Comorbidity in newly diagnosed thyroid cancer patients: a population-based study on prevalence and the impact on treatment and survival. Clin Endocrinol (Oxf). 2006; 64(4): 450–455.
19. Zadrożna A. [Raport z ogólnopolskiego badania ankietowego na temat postaw wobec palenia tytoniu] [In Polish]. TNS OBOP. 2011. (access: 2014.04.05).
20. Lambe M, Hall P, Granath F, Sadr Azodi O, Nilsson T. Coronary angioplasty and cancer risk: a population-based cohort study in Sweden. Cardiovasc Intervent Radiol. 2005; 28(1): 36–38.
21. Lun Y, Wu X, Xia Q, Han Y, Zhang X, Liu Z. Hashimoto’s thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis. Otolaryngol Head Neck Surg. 2013; 148(3): 396–402.
22. Torino F, Barnabei A, Paragliola R, Baldelli R, Appetecchia M, Corsello SM. Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid. 2013; 23(11): 1345–1366.
23. Plummer M, Herrero R, Franceschi S, Meijer CJ, Snijders P, Bosch FX, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study. Cancer Causes Control. 2003; 14(9): 805–814.
24. Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer. 2007; 14(2): 189–206.
25. Villeneuve PJ, Johnson KC, Kreiger N, Mao Y. Risk factors for prostate cancer: results from the Canadian National Enhanced Cancer Surveillance System. The Canadian Cancer Registries Epidemiology Research Group. Cancer Causes Control. 1999; 10(5): 355–367.